Clinical Trial Update: Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy [Phase 3]

View source ↗

Summary

A Phase 3 trial of AS-3201 for diabetic sensorimotor polyneuropathy has completed, with results assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy
• Diabetic Sensorimotor Polyneuropathy

Drugs mentioned

• AS-3201

Snippet

Sponsor: Sumitomo Pharma Co., Ltd. | Conditions: Diabetic Neuropathy | Phase 3 | Status: COMPLETED